Anthem officials told a judge on Monday that their counterparts at Cigna sabotaged the $48.9 billion merger deal, even refusing to divest business lines that would have won them approval by regulators.
The first three generics introduced make the biggest dent on prices. But the vast majority of generic-drug approvals from 2012 to 2017 were for the fourth, fifth, sixth or even later versions that minimally impact prices, according to a new report.
Advocates argue that price controls are needed because competition is failing as providers, insurers and manufacturers become larger and larger.
Executives from seven major drugmakers, including Bristol-Myers Squibb Co., Merck & Co. and Pfizer are set to testify before the Senate Finance Committee on drug prices.
In an unsealed False Claims Act case in California federal court, a former Regional Medical Center nurse alleges that administrators billed ICU, medical-surgical and telemetry services on an inpatient basis when the patient was still located in the emergency department.
The units bought by Abbott Laboratories are accused of submitting false Medicare claims for unnecessary devices for diabetic patients and paying kickbacks to the patients.
Insurance industry analysts are anxiously waiting for CVS Health to report its Q4 2018 financial results. It'll be the first quarter since the pharmacy behemoth closed its $70 billion deal to acquire health insurer Aetna in November.
Industry stakeholders were generally optimistic about proposed data-exchange rules, but they want regulators to ensure the information is useful to patients and clinicians.
HHS is using a public approach to enforcing its rules on healthcare stakeholders.
Healthcare industry groups have new hope that whistleblower cases will dwindle or even go away under new Attorney General William Barr.
Speaking at HIMSS19, ONC chief Dr. Donald Rucker said greater use of smartphones and APIs will drive new business models in healthcare.
Two judges ruled that the government violated its statutory obligation to pay cost-sharing reduction payments. Another case is already on appeal.